Open AccessP708: CANADIAN AND RUSSIAN EXPERIENCES OF ASCIMINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO FAILED MULTIPLE LINES OF TYROSINE KINASE INHIBITOR (TKI) THERAPY.
Author(s) -
Khadadah F.,
Turkina A. G.,
Lomaia E.,
Morozova E. V.,
Shukhov O. A.,
Petrova A.,
Chitanava T.,
Vlasova J. J.,
Kuzmina E.,
Nemchenko I.,
Chelysheva E. Y.,
Bykova A.,
Gurianova M.,
Xenocostas A.,
Busque L.,
Jamani K.,
Cerquozzi S.,
Kuruvilla P.,
Kaedbey R.,
Leber B.,
Assouline S.,
Kim D. D. H.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845716.75856.2d
Subject(s) - bosutinib , medicine , dasatinib , nilotinib , ponatinib , imatinib , cumulative incidence , myeloid leukemia , tyrosine kinase inhibitor , gastroenterology , imatinib mesylate , oncology , cohort , cancer